Skip to main
LENZ

LENZ Stock Forecast & Price Target

LENZ Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

LENZ Therapeutics is experiencing a flat quarter over quarter revenue for VIZZ, but new initiatives such as telehealth and a national TV campaign have the potential to significantly increase e-pharmacy prescriptions and drive acceleration in the VIZZ launch. Though there is currently minimal ciliary muscle stimulation in its mechanism, the company must see significant growth in the next few quarters to maintain a sustainable business model and is watching spending closely. The company's new telehealth prescribing option may introduce risk for patients with underlying retinal concerns, and its success will depend on the comprehensiveness and effectiveness of the screening questionnaire. With a reduced price target of $38 per share, this analyst maintains a Buy rating on the stock, factoring in a 25% estimated peak penetration rate and adjusted expense estimates.

Bears say

LENZ Therapeutics is facing potential competition and safety concerns with its presbyopia eye drop VIZZ, impacting its future commercial success. Despite recently announced initiatives such as the expansion of the sales force and a DTC campaign, there are still risks and uncertainties in securing market share and sustaining growth in the highly competitive ophthalmology market. Additionally, the company's valuation and financials may be negatively impacted if it fails to meet peak revenue estimates and secure sufficient funding for operations.

LENZ has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LENZ Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LENZ Therapeutics Inc (LENZ) Forecast

Analysts have given LENZ a Buy based on their latest research and market trends.

According to 5 analysts, LENZ has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LENZ Therapeutics Inc (LENZ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.